March Altus Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

March Altus Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$760K	Sell	6,199 -2,400	-28%	-$309K	4.75%	10
2016 Q2	$1M	Hold	8,599	–	–	7.76%	7
2016 Q1	$1.2M	Hold	8,599	–	–	12.38%	5
2015 Q4	$1.64M	Buy	+8,599	New	+$1.5M	15.09%	1
2015 Q3	–	Sell	-5,949	Closed	-$1.07M	–	24
2015 Q2	$1.07M	Buy	5,949 +2,269	+62%	+$392K	6.25%	6
2015 Q1	$638K	Sell	3,680 -62,280	-94%	-$11.3M	4.01%	15
2014 Q4	$12.2M	Sell	65,960 -1,120	-2%	-$208K	5.57%	6
2014 Q3	$11.1M	Sell	67,080 -2,169	-3%	-$356K	4.43%	9
2014 Q2	$10.8M	Sell	69,249 -4,862	-7%	-$768K	3.97%	10
2014 Q1	$11.3M	Sell	74,111 -17,300	-19%	-$2.75M	3.62%	12
2013 Q4	$12.2M	Buy	+91,411	New	+$11M	3.68%	9

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

March Altus Capital Management's ALXN Position: Q3 2016 in Review

March Altus Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 28% in Q3 2016, selling an estimated $309K and leaving 6,199 shares worth $760K. The position accounts for 4.75% of the portfolio, ranked #10.

March Altus Capital Management first reported a position in ALXN in Q4 2013 and has held it in 11 quarters since. The position peaked at $12.2M in Q4 2014. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

March Altus Capital Management held 6,199 shares of Alexion Pharmaceuticals worth $760K as of Q3 2016.
March Altus Capital Management sold 2,400 Alexion Pharmaceuticals shares in Q3 2016, an estimated $309K.
Alexion Pharmaceuticals made up 4.75% of March Altus Capital Management's portfolio in Q3 2016, its #10 holding.
March Altus Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and has held it in 11 quarters since.
March Altus Capital Management's Alexion Pharmaceuticals position peaked at $12.2M in Q4 2014.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.